Pulse Biosciences Shares Rise on Analyst Initiation of Coverage
On September 9, 2026, Pulse Biosciences (NASDAQ: PLSE) saw its stock rise nearly 10% after analyst Keith Hinton from Freedom Capital Markets initiated coverage with a 'buy' rating and a $73 price target. The recommendation was based on the company's proprietary nano-pulse stimulation technology for treating atrial fibrillation, which is currently in clinical trials. Hinton highlighted that successful trial outcomes could position Pulse to disrupt the market or even attract acquisition interest by mid-2027. Additionally, he noted the firm’s strong cash reserves as a positive factor. While the analyst expressed optimism about long-term potential, investors are cautioned to consider their risk tolerance due to reliance on clinical results. The Motley Fool's Stock Advisor team did not include Pulse Biosciences in its latest top 10 stock recommendations, despite past successes with companies like Netflix and Nvidia.
Tickers: $PLSE
Topics: analyst coverage atrial fibrillation ablation medical devices nano-pulse stimulation (NPS)